Reading Room

Drug Discovery Blog

Every drug discovery program has its own challenges. Scientists at Reaction Biology have 20 years of experience in problem-solving and decision making. Via blogs, we like to share some of our experiences and insight into our assays with the drug discovery community to support your journey to a preclinical drug candidate.

Seeing is believing: How imaging orthotopic models might pave the way for bladder cancer breakthroughs

Modelling bladder cancer (BC) for preclinical drug development is notoriously challenging. Due to the route of administration of BC treatments, orthotopic modelling represent the go-to-option for physiological relevance. Here we review current resources for in vivo BC research and describe the characterization of the MB49_luc bioluminescent model.

Spotlight: Cell-based kinase assay formats.

Running cell-based assays in multiple ways provides an opportunity to view a kinase inhibitor in action from different angles. At Reaction Biology, we offer three assay formats for cell-based kinase screening. In this blog, we compare the assay formats to help you choose the assay that is right for your research project.

Testing kinase inhibitors where it matters: Drug screening in intact cells

While biochemical assays will likely remain a critical entry point for novel molecules into the kinase inhibitor drug discovery pipeline, the field has collectively achieved a state of maturation that increasingly demands priority for cell-based assays right out of the gate.

Kinase inhibitors for treatment of COVID-19

The ability of several small molecule kinase inhibitors to modulate immune responses, as well as potentially block various stages in SARS-CoV-2 life cycle suggests they may have an important role in the emerging therapeutic arsenal. Vetting inhibitor performance across sufficiently diverse cell lines expressing SARS-CoV-2 relevant features will anticipate clinical success.

Biophysical characterization of compounds disrupting the SARS-CoV-2 Spike – ACE2 interaction using SPR

Without rock-solid biophysical predictors of binding affinity and kinetics, the road from molecular screening and simulation to cell-based assays and in vivo testing is virtually unnavigable. Fully characterizing your COVID-19 drug candidate with a proven SPR methodology is the fundament of the successful development of efficacious drugs.